PMID- 16144783
OWN - NLM
STAT- MEDLINE
DCOM- 20051215
LR  - 20131121
IS  - 0269-8811 (Print)
IS  - 0269-8811 (Linking)
VI  - 19
IP  - 5 Suppl
DP  - 2005 Sep
TI  - Long-acting risperidone in stable patients with schizoaffective disorder.
PG  - 22-31
AB  - Oral and long-acting risperidone has been shown to be effective for acute and 
      maintenance treatment of patients with schizoaffective disorders. The present 
      analysis investigated the efficacy and tolerability of direct transition from 
      other antipsychotics to risperidone long-acting injectable in patients with 
      schizoaffective disorder. Patients aged > or = 18 years with schizoaffective 
      disorder (DSM-IV), who required a change of medication, received risperidone 
      long-acting injectable 25 mg (increased to 37.5 or 50 mg, if necessary) every 2 
      weeks for 6 months. The analysis included 249 patients (47% male; mean age 43 
      years), of whom 74% completed the 6-month study. Mean scores for the total 
      Positive and Negative Syndrome Scale (PANSS) and all three subscales were 
      significantly reduced from baseline to week 4 (p < 0.001), with further 
      improvements until treatment endpoint. Significant improvements from baseline to 
      endpoint were seen in the mood symptom domains of anxiety/depression (10.4+/-4.1 
      vs 8.7+/-3.9) and uncontrolled hostility/excitement (7.6+/-3.6 vs 6.9+/-3.8). 
      Mean Global Assessment of Function (GAF) score improved significantly from 
      59.4+/-15.6 at baseline to 66.4+/-17.7 (p < 0.001) at endpoint. Of 87 patients 
      hospitalized at baseline, 67% were discharged at endpoint. Both quality of life 
      (SF-36) and satisfaction with treatment were improved significantly at endpoint. 
      Total ESRS scores fell progressively throughout the study, and the reduction was 
      already statistically significant (p < 0.001) at 4 weeks. Small but statistically 
      significant (p < 0.001) mean shifts of 1.8% were seen in body weight and Body 
      Mass Index (BMI). Patients with schizoaffective disorder derived several benefits 
      from a change to risperidone long-acting injectable, including reductions in 
      psychiatric symptoms (particularly the mood symptom domains) and a reduction in 
      the severity of drug-induced neurological movement disorders.
FAU - Mohl, A
AU  - Mohl A
AD  - Psychiatrische Dienste Aargau AG, EPD, Baden, Switzerland. andreas.mohl@pdag.ch
FAU - Westlye, K
AU  - Westlye K
FAU - Opjordsmoen, S
AU  - Opjordsmoen S
FAU - Lex, A
AU  - Lex A
FAU - Schreiner, A
AU  - Schreiner A
FAU - Benoit, M
AU  - Benoit M
FAU - Braunig, P
AU  - Braunig P
FAU - Medori, R
AU  - Medori R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Body Weight/drug effects
MH  - Delayed-Action Preparations
MH  - Female
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy/psychology
MH  - Quality of Life
MH  - Risperidone/administration & dosage/adverse effects/*therapeutic use
MH  - Weight Gain/drug effects
EDAT- 2005/09/08 09:00
MHDA- 2005/12/16 09:00
CRDT- 2005/09/08 09:00
PHST- 2005/09/08 09:00 [pubmed]
PHST- 2005/12/16 09:00 [medline]
PHST- 2005/09/08 09:00 [entrez]
AID - 19/5_suppl/22 [pii]
AID - 10.1177/0269881105056515 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2005 Sep;19(5 Suppl):22-31. doi: 10.1177/0269881105056515.